To include your compound in the COVID-19 Resource Center, submit it here.

Exjade deferasirox regulatory update

EMA's CHMP recommended against expanding the label of Exjade deferasirox from Novartis to include first-line treatment of chronic iron overload in patients ages >=6 years

Read the full 256 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE